INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded INmune Bio from “Sell” to “Hold,” while Weiss Ratings separately downgraded the stock from “Sell (D-)” to “Sell (E+).” MarketBeat’s overall analyst consensus remains “Moderate Buy,” based on one Strong Buy and one Sell rating.
• INMB opened at $2.08, with a $55.42 million market capitalization and a 52-week trading range of $1.09 to $2.61. The company reported a quarterly loss of $0.05 per share, beating the consensus estimate for a $0.21 loss.
• Institutional investors own 12.72% of INmune Bio, with several hedge funds recently initiating positions. The clinical-stage immunology company is developing therapies targeting serious diseases, including cancer and neurodegenerative conditions.

INmune Bio (NASDAQ:INMB - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Separately, Weiss Ratings downgraded INmune Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy".

INmune Bio Stock Performance

NASDAQ INMB opened at $2.08 on Friday. The firm has a market capitalization of $55.42 million, a P/E ratio of -3.11 and a beta of 0.97. The stock has a 50-day simple moving average of $1.63 and a two-hundred day simple moving average of $1.48. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $2.61.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.16.

Institutional Investors Weigh In On INmune Bio

Several hedge funds have recently modified their holdings of INMB. Quadrature Capital Ltd acquired a new stake in shares of INmune Bio during the 4th quarter valued at about $26,000. Intech Investment Management LLC acquired a new position in INmune Bio in the 2nd quarter worth about $26,000. Squarepoint Ops LLC acquired a new position in INmune Bio in the 3rd quarter worth about $30,000. Virtu Financial LLC purchased a new position in INmune Bio during the fourth quarter worth approximately $32,000. Finally, Bank of New York Mellon Corp purchased a new position in INmune Bio during the second quarter worth approximately $35,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company's research and development efforts concentrate on modulating cellular pathways to restore and enhance the body's natural defenses, particularly in oncology and neurodegenerative conditions.

The company's lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source